Glimepiride reduces CD14 expression and cytokine secretion from macrophages by Victoria Ingham et al.
JOURNAL OF 
NEUROINFLAMMATION
Ingham et al. Journal of Neuroinflammation 2014, 11:115
http://www.jneuroinflammation.com/content/11/1/115RESEARCH Open AccessGlimepiride reduces CD14 expression and
cytokine secretion from macrophages
Victoria Ingham1, Alun Williams2 and Clive Bate1*Abstract
Background: Activated microglia are associated with deposits of aggregated proteins within the brains of patients
with Alzheimer’s disease (AD), Parkinson’s disease (PD) and prion diseases. Since the cytokines secreted from
activated microglia are thought to contribute to the pathogenesis of these neurodegenerative diseases,
compounds that suppress cytokine production have been identified as potential therapeutic targets. CD14 is a
glycosylphosphatidylinositol (GPI)- anchored protein that is part of a receptor complex that mediates microglial
responses to peptides that accumulate in prion disease (PrP82-146), AD (amyloid-β (Aβ)42) and PD (α-synuclein
(αSN)). As some GPI-anchored proteins are released from cells by treatment with glimepiride, a sulphonylurea used
for the treatment of diabetes, the effects of glimepiride upon CD14 expression and cytokine production from
cultured macrophages were studied.
Methods: RAW 264 cells and microglial cells were treated with glimepiride or phosphatidylinositol (PI)-phospholipase
C (PLC) and the expression of cell receptors was analysed by ELISA and immunoblot. Treated cells were subsequently
incubated with Aβ42, αSN, PrP82-146 or lipopolysaccharide (LPS) and the amounts of Toll-like receptor (TLR)-4, tumour
necrosis factor (TNF), interleukin (IL)-1 and IL-6 measured.
Results: Glimepiride released CD14 from RAW 264 cells and microglial cells. Pre-treatment with glimepiride significantly
reduced TNF, IL-1 and IL-6 secretion from RAW 264 and microglial cells incubated with LPS, Aβ42, αSN and PrP82-146.
Glimepiride also reduced the LPS, Aβ42, αSN and PrP82-146-induced translocation of TLR-4 into membrane rafts that is
associated with cell activation. These effects of glimepiride were also seen after digestion of RAW 264 cells with
PI-phospholipase C (PLC). In addition, the effects of glimepiride were blocked by pharmacological inhibition of GPI-PLC.
The cytokine production was CD14-dependent; it was reduced in microglia from CD14 knockout mice and was blocked
by antiserum to CD14.
Conclusions: RAW 264 and microglial cell responses to Aβ1–42, αSN, PrP82-146 and LPS are dependent upon CD14
expression. Glimepiride induced the shedding of CD14 from cells by activation of GPI-PLC and consequently reduced
cytokine production in response to Aβ42, αSN, PrP82-146 and LPS. These results suggest that glimepiride acts as a novel
anti-inflammatory agent that could modify the progression of neurodegenerative diseases.Background
The deposition of aggregated proteins within the brain is a
common feature of neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s disease (PD) and
prion diseases. These aggregates are often surrounded by
activated microglial cells, the resident macrophage-like
cells of the brain [1-3] and, in vitro aggregated forms of
disease-associated peptides stimulate cytokine secretion* Correspondence: cbate@rvc.ac.uk
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unless otherwise stated.from microglia/macrophages [3-6]. Numerous studies
suggest that cytokine-induced neuroinflammation contrib-
utes to the clinical progression of AD, PD and prion dis-
eases [7-9]. For example, epidemiological studies reported
that the use of non-steroidal anti-inflammatory drugs de-
layed the progression of dementia, PD and AD [10-12]
and the beneficial effects of statin therapy on dementia
[13] have been attributed to their anti-inflammatory prop-
erties [14]. While it is difficult to ascertain the extent of
cytokine secretion that occurs within the brain directly,
the addition of fibrillar forms of amyloid-β (Aβ1–42),
α-synuclein (αSN) or the prion-derived peptide (PrP82-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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macrophages and microglia [3,15-17]. In this study the re-
sponses of a macrophage cell line (RAW 264 cells) and
primary microglial cells that secrete tumour necrosis fac-
tor (TNF) and interleukins (IL) 1 and IL-6 [18] in re-
sponse to PrP82-146, Aβ1–42 and αSN were studied.
It has been suggested that drugs that reduce cytokine
secretion from macrophages might be of therapeutic
benefit in AD and PD [19]. While multiple receptors have
been reported to be involved in macrophage responses to
aggregated neurotoxic proteins [20], including scavenger
receptors [21] and CD40 [22], other studies implicate
CD14, a protein that is highly expressed on myeloid cells
including microglia [23], as a key component of the recep-
tor complex that mediates cytokine secretion induced by
fibrillar Aβ peptides [16], prion-damaged neurons [24]
and lipopolysaccharide (LPS) [25,26]. Furthermore, the
genetic deletion of CD14 attenuates pathology in a murine
model of AD [27]. We therefore hypothesised that any
compound that reduces the expression of CD14 on micro-
glia/macrophages may also reduce cytokine secretion and
consequently ameliorate the rate of cognitive decline. Lit-
tle is known about what factors control the expression of
CD14 on macrophages. However, CD14 is linked to the
membrane via a glycosylphosphatidylinositol (GPI) anchor
[28] and like other GPI-anchored proteins is found in sol-
uble forms. Thus, soluble CD14 found in the bloodstream
can reduce cytokine secretion from macrophages [29] and
prevent mortality in LPS-treated mice [30]. More recently,
the concentrations of soluble CD14 were found to be ele-
vated in AD and PD patients and were associated with
glial cell suppression [31]. Collectively such observations
suggest that either a reduction of cell-associated CD14, or
an increase in soluble CD14 in extracellular fluids, can re-
duce cytokine secretion from macrophages.
Glimepiride, a sulphonylurea used to treat diabetes [32],
is able to mimic insulin signalling and activate an en-
dogenous GPI-phospholipase C (PLC) [33] resulting in
the release of some GPI-anchored proteins from the sur-
face of adipocytes [34] and neurons [35]. For this reason,
its effects upon macrophages were examined in this study.
We report that glimepiride-treated RAW 264 and micro-
glial cells expressed lower amounts of CD14 and produced
fewer cytokines when incubated with PrP82-146, Aβ1–42,
αSN or LPS than control cells.
Methods
Cell lines
The murine RAW 264 cell line was grown in Ham’s F12
medium supplemented with 2 mM glutamine, 5% foetal
calf serum (FCS) (PAA, www.gelifesciences.com/PAA) and
standard antibiotics (100 U/ml penicillin and 100 μg/ml
streptomycin - Invitrogen, www.lifetechnologies.com/uk).
Cells were seeded in 48-well plates at 2 x 105 cells per welland allowed to adhere overnight. Cells were pre-treated
with test compounds including glimepiride, glipizide,
p-chloromercuriphenylsulphonate (p-CMPS), polymyxin
B or phosphatidylinositol (PI)-PLC derived from Bacillus
cereus, (all obtained from Sigma) or with antibodies
to CD14 (goat polyclonal IgG anti-mouse CD14 (R&D
Systems, www.rndsystems.com), PrPC (mouse mAb 4 F2)
or CD55 (rat mAb 3D5 Abcam) for one hour before the
addition of LPS (Sigma, www.sigmaaldrich.com), PrP82-
146, αSN or Aβ42. Cell supernatants were collected 24
hours later and tested for cytokines or CD14. Cell extracts
were also collected and tested for CD14 and Toll-like
receptor (TLR)-4. Experiments were performed in tripli-
cate wells. Levels of TNF, IL-1 and IL-6 were assayed by
sandwich enzyme-linked immunoassays (ELISA)s using
matched pairs of antibodies (see below).
Microglial cells
These were prepared by dissociating cerebral cortices of
newborn mouse pups derived from C57Bl/B6J, CD14
wild type and from C57Bl/B6J, CD14 knockout mice
(Jackson Laboratory, www.jax.org) as described [36]. Cell
suspensions were prepared by repeated passage through
a fine bore pipette and debris was removed by filtration
through a 100 μM cell strainer. Cells were suspended in
Ham’s F12 medium containing 2 mM glutamine, stand-
ard antibiotics and 10% FCS, and placed into poly-
L-lysine coated 75 cm3 flasks. Cultures were maintained
at 37°C with 5% CO2 for two weeks or until glial cul-
tures were confluent. Microglial cells were isolated by
shaking cultures at 260 rpm for 2 hours. Detached cells
were collected, counted and dispensed at 2 × 105 cells per
well in 48-well plates. Greater than 90% of cells stained
positive for the mouse macrophage marker protein F4/80
(Serotec, www.abdserotec.com/).
Cell extracts
At the end of treatments, cells were washed twice in PBS
and homogenised in an extraction buffer containing 10
mM Tris-HCl at pH 7.4, 100 mM NaCl, 10 mM ethylene-
diaminetetraacetic acid (EDTA), 0.5% Nonidet P-40, 0.5%
sodium deoxycholate, 0.2% sodium dodecyl sulphate (SDS)
and mixed protease inhibitors (4-(2-aminoethyl) benzene-
sulfonyl fluoride, aprotinin, leupeptin, bestatin, pepstatin A
and E-46 - Sigma) at 106 cells/ml. Membranes were pre-
pared by repeated passage with a Wheaton homogeniser;
nuclei and large fragments were removed by centrifugation
(300 × g for 5 minutes).
Isolation of detergent resistant membranes (DRMs)/lipid rafts
Cells were lysed in an ice-cold buffer containing 1% Triton
X-100, 10 mM Tris-HCl (pH 7.2), 100 mM NaCl, 10 mM
EDTA and mixed protease inhibitors (106 cells/ml). Mem-
branes were prepared by homogenisation and nuclei and
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for 5 minutes). The post nuclear supernatant was incu-
bated on ice for 60 minutes prior to further centrifugation
(16,000 × g for 30 minutes at 4°C). The soluble material
was reserved as the normal cell membrane. The pellets
were solubilised in extraction buffer (10 mM Tris-HCl,
10 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5%
sodium deoxycholate and 0.2% SDS and mixed protease
inhibitors, centrifuged again (10 minutes at 16,000 × g)
and the supernatant reserved as the lipid raft fraction.
IL-1β ELISA
A monoclonal antibody to IL-1β (R&D systems) was di-
luted to 2 μg/ml in carbonate buffer and dispensed in
96-well Maxisorb Immunoplates (Nunc, Roskilde, Denmark)
overnight. Samples were added for one hour, followed
by the secondary antibody (a biotinylated goat anti-mouse
IL-1β (R&D systems)). Extravidin-alkaline phosphatase
(1:1,000, Sigma) was added for 1 hour after which 1 mg/ml
4-nitrophenyl phosphate substrate (Sigma) was added.
After 20 minutes, plates were read at 450 nM and results
were calculated by reference to a standard curve of recom-
binant murine IL-1β (R&D systems).
IL-6 ELISA
A monoclonal antibody to IL-6 was diluted to 2 μg/ml
in carbonate buffer and dispensed in 96-well Maxisorb
Immunoplates overnight. Samples were added for one
hour, followed by the secondary antibody (a polyclonal
anti-mouse IL-6 conjugated to alkaline phosphatase (R&D
systems)) which was detected using 1 mg/ml 4-nitrophenyl
phosphate. Plates were read at 450 nM and results were
calculated by reference to a standard curve of recombinant
murine IL-6 (R&D systems).
TNF ELISA
Polyclonal IgG to TNF (R&D systems) was diluted to 2
μg/ml in carbonate buffer and dispensed in 96-well Maxi-
sorb Immunoplates overnight. Samples were added for
one hour, followed by the detection antibody, a biotinyl-
ated anti-mouse TNF polyclonal antibody (R&D systems)
added at 200 ng/ml. A 1:5,000 dilution of extravidin-
alkaline phosphatase was then added for a further hour
followed by the addition of 1 mg/ml 4-nitrophenyl phos-
phate. Plates were read at 450 nM and results were calcu-
lated by reference to a standard curve of recombinant
murine TNF (R&D systems).
CD14 ELISA
Maxisorb Immunoplates were coated with 0.5 μg/ml rat
IgG1 anti-mouse CD14 mAb (clone RmC5-3) (BD Biosci-
ences, www.bdbiosciences.com). Samples were applied and
the amount of bound CD14 was measured using a goat
polyclonal IgG anti-mouse CD14 (R&D Systems), followedby anti-goat IgG conjugated to alkaline phosphatase (Sigma)
and 1 mg/ml 4-nitrophenyl phosphate (Sigma). Absorb-
ance was measured on a microplate reader at 405 nm. Re-
sults were reported as units CD14 where 100 units =
amount of CD14 in 106 control RAW 264 cells.
TLR-4 ELISA
Maxisorb Immunoplates were coated with 0.5 μg/ml of
mouse monoclonal to TLR-4 (Abcam - ab22048) (epitope
100 to 200) and blocked with 5% milk powder. Samples
were applied (one hour at room temperature) and the
amounts of TLR-4 were measured using a rabbit poly-
clonal IgG to TLR-4 (Abcam - ab13556) (epitope 420 to
435), followed by anti-rabbit IgG conjugated to alkaline
phosphatase and 1 mg/ml 4-nitrophenyl phosphate. Ab-
sorbance was measured on a microplate reader at 405 nm.
Results were reported as% TLR-4 where 100% = amount
of TLR-4 in cell extracts from control RAW 264 cells.
PrP82-146 ELISA
The amount of PrP82-146 in cell extracts was deter-
mined by ELISA as described [35]. Maxisorb Immuno-
plates were coated with mAb 3 F4 (Abcam, www.abcam.
com). Samples were boiled with 0.2% SDS to denature
peptide and incubated for one hour. Bound PrP82-146
was detected with biotinylated ICSM35 (a gift from Dr
Mourad Tayebi), followed by extravidin-alkaline phos-
phatase and 1 mg/ml 4-nitrophenyl phosphate. Absorb-
ance was measured on a microplate reader at 405 nm
and the amount of PrP82-146 in cell extracts was calcu-
lated by reference to a standard curve of PrP82-146.
Aβ42 ELISA
Maxisorb Immunoplates were coated with mAb 4G8 (epi-
tope 17 to 24) (Covance, www.bioscience.co.uk/covance)
in carbonate buffer overnight. Plates were blocked with
5% milk powder in PBS-Tween and samples were applied.
The detection antibody was an Aβ42 selective rabbit mAb
BA3-9 (Covance) followed by biotinylated anti-rabbit IgG
(Sigma). Total Aβ was visualised by addition of 1 mg/ml
4-nitrophenyl phosphate and optical density was read in a
spectrophotometer at 405 nm. Absorbance was measured
on a microplate reader at 405 nm and results were calcu-
lated by comparison to serial dilutions of synthetic Aβ1–42.
Western blot analysis
Samples were mixed with Laemmli buffer, heated to 95°C
and subjected to electrophoresis on 15% polyacrylamide
gels. Proteins were transferred onto a Hybond-P PVDF
membrane (Amersham Biotech, www.gelifesciences.com)
by semi-dry blotting. Membranes were blocked with 10%
milk powder and incubated with either mAb ICSM35 (to
detect PrPC), goat polyclonal IgG anti-mouse CD14 (R&D
Systems), sheep polyclonal anti-CD55 (R&D Systems) or
Figure 1 Glimepiride releases CD14 from RAW 264 cells. (A) The
amounts of CD14 in RAW 264 cells treated for one hour with control
medium (□) or glimepiride (■) as shown. Values are means ± SD,
from triplicate experiments performed 4 times, n = 12. (B) The
amounts of CD14 in supernatants from RAW 264 cells treated for
one hour with control medium (□) or glimepiride as shown (■).
Values are means ± SD, from triplicate experiments performed 4
times, n = 12. (C) Immunoblots showing the amounts of CD14, PrPC,
CD55 and caveolin in extracts from RAW 264 cells treated for 1 hour
with control medium (i) or 5 μM glimepiride (ii). (D) The amounts of
CD14 in cells (□) or supernatants (■) from microglial cells treated for
1 hour with control medium, 5 μM glimepiride or 5 μM glipizide.
Values are mean units CD14 ± SD, from triplicate experiments
performed 3 times, n = 9. *Cellular CD14 significantly less than
control cells. **supernatant CD14 significantly greater than control
supernatants. (E) Blot showing the amounts of CD14 in supernatants
from microglial cells treated with concentrations of glimepiride as
shown for one hour.
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millipore.com), followed by a secondary anti-mouse, rabbit
or goat IgG conjugated to peroxidase (Sigma). Bound anti-
body was visualised using enhanced chemiluminescence.
Peptides
Synthetic peptides containing amino acids 82 to 146 of the
human PrP protein (PrP82-146) corresponding to a PrP
fragment found in prion-infected brains, and a control pep-
tide (PrP82-146scrambled) were supplied by Professor Mario
Salmona (Mario Negri Institute, Milan). A synthetic peptide
containing the amino acid residues 1 to 42 of the Aβ protein
(Aβ1–42) and a control peptide consisting of the same amino
acids in reverse order (Aβ42–1) were obtained from Bachem.
Stock solutions of peptides were stored at 1 mM in di-
methyl sulphoxide and thawed on the day of use before di-
lution in culture medium, sonication and addition to cells.
Recombinant αSN and βSN were purchased from Sigma.
Statistical methods
Differences between treatment groups were assessed
using Student’s, two sample, paired-t tests. In all tests
statistical significance was set at the 5% level.
Results
Glimepiride stimulated the release of CD14 from RAW
264 cells
Since glimepiride stimulated the release of some GPI-
anchored proteins from adipocytes [34] and neurons
[35] the effect of glimepiride on the expression of GPI-
anchored proteins in RAW 264 cells was examined. The
amount of CD14 in RAW 264 cells treated with glime-
piride for one hour was reduced in a dose-dependent
manner (Figure 1A); the loss of CD14 from RAW 264
cells was accompanied by a corresponding increase in
the amount of CD14 in the supernatant of these cells
(Figure 1B). These effects occurred at non-toxic concen-
trations of glimepiride, thus the addition of 5 μM glime-
piride did not significantly alter cell survival as measured
by thiazolyl blue tetrazolium (97% cell viability ± 6 com-
pared with 100% ± 7, n = 12, P = 0.24). Pre-treatment of
RAW 264 cells with 5 μM glipizide, another sulphony-
lurea used to treat diabetes, did not affect the amounts of
CD14 in cells (data not shown). The effects of glimepiride
were not CD14 specific; it also reduced the amount of the
GPI-anchored cellular prion protein (PrPC) in cells, but
did not affect the amounts of GPI-anchored CD55 or cav-
eolin (Figure 1C). Glimepiride, but not glipizide, had a
similar effect upon microglial cells; treatment with 5 μM
glimepiride reduced cellular CD14 and increased the
amounts of soluble CD14 in the supernatant (Figure 1D).
Glimepiride caused a dose-dependent increase in the
amounts of soluble CD14 as measured by Western blot
(Figure 1E).Glimepiride reduced cytokine secretion from RAW 264 cells
The activation of microglial cells by aggregated peptides
is thought to affect the progression of prion diseases.
The addition of PrP82-146 increased the secretion of
TNF from RAW 264 cells (Figure 2A). TNF production
from cells incubated with a control peptide (PrP82-
146scrambled) was not significantly different from cells
treated with control medium. The inclusion of 1 μg/ml
polymyxin B, an antibiotic that blocks the effects of LPS,
did not affect PrP82-146-induced TNF production, indi-
cating that cytokine production was not due to contam-
ination with this common bacterial contaminant. The
effects of glimepiride on TNF secretion were then tested.
The addition of 5 μM glimepiride or 5 μM glipizide did
Figure 2 Glimepiride reduces cytokine secretion from RAW 264
cells incubated with PrP82-146. (A) The concentrations of TNF
produced by RAW 264 cells incubated with PrP82-146 (●), PrP82-
146scrambled (■) or PrP82-146 and 1 μg/ml polymyxin B (□). Values
are means ± SD from triplicate experiments performed 4 times, n = 12.
(B) The concentrations of TNF produced by RAW 264 cells pre-treated
with control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (□)
and incubated with PrP82-146. Values are means ± SD from triplicate
experiments performed 4 times, n = 12. (C) There was a significant
correlation between the amounts of cellular CD14 of RAW 264 cells
treated with glimepiride (0.3 to 5 μM) for 1 hour and TNF production
after the addition of 50 μM PrP82-146, Pearson’s coefficient = 0.858,
P < 0.01. (D) The concentrations of IL-1β produced by RAW 264 cells
pre-treated with control medium (●), 5 μM glimepiride (○) or 5 μM
glipizide (□) and incubated with PrP82-146. Values are means ± SD
from triplicate experiments performed 4 times, n = 12. (E) The
concentrations of IL-6 produced by RAW 264 cells pre-treated with
control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (□) and
incubated with PrP82-146. Values are means ± SD from triplicate
experiments performed 4 times, n = 12.
Figure 3 Glimepiride reduces cytokine secretion from RAW 264
cells incubated with Aβ. (A) The concentrations of TNF produced
by RAW 264 cells incubated with Aβ1–42 (●), Aβ42–1 (■) or Aβ1–42 and 1
μg/ml polymyxin B (□). Values are means ± SD from triplicate
experiments performed 4 times, n = 12. (B) The concentrations of TNF
produced by RAW 264 cells pre-treated with control medium (●) 5 μM
glimepiride (○) or 5 μM glipizide (□) and incubated with Aβ1–42. Values
are means ± SD from triplicate experiments performed 4 times, n = 12.
(C) The concentrations of IL-1β produced by RAW 264 cells pre-treated
with control medium (●) 5 μM glimepiride (○) or 5 μM glipizide (□)
and incubated with Aβ1–42. Values are means ± SD from triplicate
experiments performed 4 times, n = 12. (D) The concentrations of IL-6
produced by RAW 264 cells pre-treated with control medium (●), 5 μM
glimepiride (○) or 5 μM glipizide (□) and incubated with Aβ1–42. Values
are means ± SD from triplicate experiments performed 4 times, n = 12.
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However, pre-treatment with 5 μM glimepiride, but not
5 μM glipizide, significantly reduced the secretion of
TNF from RAW 264 cells incubated with PrP82-146
(Figure 2B). The effects of glimepiride upon TNF pro-
duction were dose-dependent; a significant correlation
was observed between the amounts of cellular CD14and TNF production following the addition of 50 μM
PrP82-146 (Figure 2C). Similarly, pre-treatment of RAW
264 cells with 5 μM glimepiride, but not glipizide, signifi-
cantly reduced the secretion of IL-1β (Figure 2D) or IL-6
(Figure 2E).
The addition of Aβ1–42, but not Aβ42–1, also caused
the secretion of TNF from RAW 264 cells (Figure 3A).
The Aβ1–42-induced secretion of TNF was not affected
by the inclusion of 1 μg/ml polymyxin B. Pre-treatment
with 5 μM glimepiride, but not 5 μM glipizide, signifi-
cantly reduced the Aβ1–42-induced secretion of TNF
(Figure 3B), IL-1β (Figure 3C) or IL-6 (Figure 3D).
Similarly, the addition of αSN, but not βSN, caused
the secretion of TNF from RAW 264 cells (Figure 4A).
The αSN-induced secretion of TNF was not affected
by the inclusion of 1 μg/ml polymyxin B. Pre-treatment
with 5 μM glimepiride, but not 5 μM glipizide, sig-
nificantly reduced the αSN-induced secretion of TNF
(Figure 4B), IL-1β (Figure 4C) or IL-6 (Figure 4D) from
RAW 264 cells.
Figure 4 Glimepiride reduces cytokine secretion from RAW 264
cells incubated with αSN. (A) The concentrations of TNF produced
by RAW 264 cells incubated with αSN (●), βSN (■) or αSN and 1 μg/ml
polymyxin B (□). Values are means ± SD from triplicate experiments
performed 4 times, n = 12. (B) The concentrations of TNF produced by
RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride
(○) or 5 μM glipizide (□) and incubated with αSN. Values are means ± SD
from triplicate experiments performed 4 times, n = 12. (C) The
concentrations of IL-1β produced by RAW 264 cells pre-treated with
control medium (●) or 5 μM glimepiride (○) or 5 μM glipizide (□) and
incubated with αSN. Values are means ± SD from triplicate experiments
performed 4 times, n = 12. (D) The concentrations of IL-6 produced by
RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride (○)
or 5 μM glipizide (□) and incubated with αSN. Values are means ± SD
from triplicate experiments performed 4 times, n = 12.
Figure 5 Glimepiride reduces cytokine secretion from
microglial cells incubated with PrP82-146 or Aβ1–42. (A)
The concentrations of TNF produced by microglial cells pre-treated
for 1 hour with control medium (■), 5 μM glimepiride (□) or 5 μM
glipizide (striped bars) and incubated with control medium, 50 μM
PrP82-146 or 50 μM Aβ1–42 as shown. Values are means ± SD from
triplicate experiments performed 3 times, n = 9. *TNF significantly less
than control cells incubated with peptides. (B) The concentrations of
TNF produced by microglial cells pre-treated with control medium (●)
or 5 μM glimepiride for 1 hour (□), or pre-treated with 5 μM glimepirde
for 1 hour and washed 3 times with PBS (striped bars) and incubated
with 50 μM PrP82-146 or 50 μM Aβ1–42 as shown. Values are
means ± SD from triplicate experiments performed 3 times, n = 9.
*TNF significantly less than control cells incubated with peptides.
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Responses from RAW 264 cells were compared to those
obtained with primary microglial cells which produced
similar amounts of TNF when incubated with either 50
μM PrP82-146 or 50 μM Aβ1–42. The amounts of TNF
secreted from microglial cells incubated with control
peptides, PrP82-146scrambled or Aβ42–1, were not sig-
nificantly higher than those from control microglial cells
(data not shown). Pre-treatment of microglial cells with
5 μM glimepiride, but not 5 μM glipizide, significantly
reduced TNF secretion in response to 50 μM PrP82-146
or 50 μM Aβ1–42 (Figure 5A). It was not clear whether
soluble CD14 released from glimepiride-treated cells
bound to PrP and Aβ peptides, thus preventing their
interaction with microglial cells, or whether glimepiride
caused microglial cells to be hyporesponsive to PrP and
Aβ peptides. Therefore, microglial cells were treated
with 5 μM glimepiride for 1 hour and then thoroughly
washed to remove any soluble receptors before theaddition of 50 μM PrP82-146 or 50 μM Aβ1–42. We re-
port that washed cells produced less TNF than control
cells when incubated with 50 μM PrP82-146 or 50 μM
Aβ1–42 (Figure 5B).
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A time course study was used to determine whether the
effects of glimepiride on RAW 264 and microglial cells
were permanent. After treatment with 5 μM glimepiride,
there was a time-dependent increase in cell-associated
CD14 in both RAW 264 cells (Figure 6A) and microglial
cells (Figure 6C). Similarly, the capacity of RAW 264 and
microglial cells to produce TNF in response to PrP82-146
also showed a time-dependent increase (Figures 6B and D).
Glimepiride reduced LPS-induced cytokine secretion
The effect of glimepiride on cytokine secretion from
RAW 264 cells incubated with LPS was also examined.
The addition of LPS caused a dose-dependent increase
in the secretion of TNF, IL-1β and IL-6 which was
reduced by pre-treatment with 5 μM glimepiride
(Figure 7A, B and C). In contrast, cytokine secretion was
not affected by pre-treatment with 5 μM glipizide. Simi-
larly, pre-treatment with 5 μM glimepiride, but not 5Figure 6 RAW264 and microglial cells recover from
glimepiride-induced suppression of cytokine production. (A)
The amounts of CD14 in RAW 264 cells treated with control medium
(□) or 5 μM glimepiride for time periods as shown (■). Values are
means ± SD from triplicate experiments performed twice, n = 6. (B) The
concentrations of TNF produced by RAW 264 cells pre-treated with
control medium (□) or 5 μM glimepiride for time periods as shown (■)
and incubated with 50 μM PrP82-146 for 24 hours. Values are
means ± SD from triplicate experiments performed twice, n = 6.
(C) The amounts of CD14 in microglial cells treated with control
medium (□) or 5 μM glimepiride for time periods as shown (■). Values
are means ± SD from triplicate experiments performed twice, n = 6.
(D) The concentrations of TNF produced by microglial cells pre-treated
with control medium (□) or 5 μM glimepiride for time periods as
shown (■) and incubated with 50 μM PrP82-146 for 24 hours. Values
are means ± SD from triplicate experiments performed twice, n = 6.
Figure 7 Glimepiride reduces lipopolysaccharide (LPS)-induced
cytokine secretion. (A) The concentrations of TNF produced by
RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride
(○) or 5 μM glipizide (■) and incubated with LPS. Values are means ± SD
from triplicate experiments performed 4 times, n = 12. (B) The
concentrations of IL-1β produced by RAW 264 cells pre-treated with
control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (■) and
incubated with LPS. Values are means ± SD from triplicate experiments
performed 4 times, n = 12. (C) The concentrations of IL-6 produced by
RAW 264 cells pre-treated with control medium (●), 5 μM glimepiride
(○) or 5 μM glipizide (■) and incubated with LPS. Values are means ± SD
from triplicate experiments performed 4 times, n = 12. (D) The
concentrations of TNF produced by microglial cells pre-treated with
control medium (●), 5 μM glimepiride (○) or 5 μM glipizide (■) and
incubated with LPS. Values are means ± SD from triplicate experiments
performed 4 times, n = 12. (E) The concentrations of TNF produced by
RAW 264 cells pre-treated with control medium (□) or glimepiride as
shown (■) and incubated with 10 ng/ml LPS. Values are means ± SD
from triplicate experiments performed 3 times, n = 9. (F) There was a
significant correlation between the CD14 content of RAW 264 cells
treated with glimepiride (0.3 to 5 μM) and the concentrations of TNF
produced in response to 10 ng/ml LPS, Pearson’s coefficient = 0.886.μM glipizide, reduced TNF production from primary
microglial cells incubated with LPS (Figure 7D). When
RAW 264 cells were pre-treated with different concen-
trations of glimepiride before the addition of 10 ng/ml
LPS, glimepiride reduced TNF secretion in a dose-
dependent manner (Figure 7E). When concentrations of
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5 μM) were plotted against TNF production in response
to LPS, a significant correlation was observed (Figure 7F).
PI-PLC digestion reduced cytokine secretion from RAW
264 cells
The molecular mechanisms of glimepiride-induced im-
munosuppression were examined. Since glimepiride acti-
vates an endogenous GPI-PLC causing the release of GPI-
anchored proteins [34,35], we hypothesised that treatment
with PI-PLC would have similar effects to glimepiride on
macrophages. Treatment of RAW 264 cells with 0.2 units
PI-PLC/ml for 1 hour significantly reduced the amount of
cell associated CD14 (7 units ± 3 compared with 100 ± 10,
n = 9, P < 0.05) and increased the amount of CD14 in
cell supernatants (81 units ± 6 compared with 7 units ±
4, n = 9, P < 0.05), thus replicating some of the effects of
glimepiride upon RAW 264 cells. Critically, RAW 264
cells pre-treated with of 0.2 units/ml PI-PLC for 1 hour
produced significantly less TNF, Il-1β and IL-6 when
incubated with 50 μM PrP82-146, Aβ1–42 or αSN than
did vehicle-treated cells (Figure 8A, B and C). TheseFigure 8 PI-PLC digestion reduced cytokine secretion from RAW
264 cells. (A) The concentrations of TNF produced by RAW 264 cells
pre-treated with control medium (□) or PI-PLC (■) and incubated with
50 μM PrP82-146, Aβ1–42 or αSN. Values are means ± SD from triplicate
experiments performed 4 times, n = 12. *TNF significantly less than control
cells incubated with peptides. (B) The concentrations of IL-1β produced
by RAW 264 cells pre-treated with control medium (□) or PI-PLC (■) and
incubated with 50 μM PrP82-146, Aβ1–42 or αSN. Values are means ± SD
from duplicate experiments performed 4 times, n = 8. *IL-1β significantly
less than control cells incubated with peptides. (C) The concentrations of
IL-6 produced by RAW 264 cells pre-treated with control medium (□) or
PI-PLC (■) and incubated with 50 μM PrP82-146, Aβ1–42 or αSN. Values are
means ± SD from duplicate experiments performed 4 times, n = 8. *IL-6
significantly less than control cells incubated with peptides. *IL-6
significantly less than control cells incubated with peptides.cells also produced less TNF, IL-1β and IL-6 in re-
sponse to LPS (Figure 9A, B and C).
Next, we sought to reverse the effect of glimepiride
by inhibiting the activity of GPI-PLC. The effects of
pCMPS (an inhibitor of GPI-PLC [37]) upon glimepiride-
induced suppression of cytokine production were studied.
Treatment with 200 μM p-CMPS did not affect the
amount of CD14 in RAW 264 cells (94 units ± 11 com-
pared with 100 ± 8, n = 9, P = 0.5), nor did it affect TNF
secretion from RAW 264 cells incubated with 10 ng/ml
LPS (2,614 pg/ml ± 338 compared with 2,549 pg/ml ± 306,
n = 9, P = 0.7). However, the addition of 200 μM p-CMPS
to RAW 264 cells reversed the effect of glimepiride on
cells, it prevented the glimepiride-induced reduction
in cellular CD14 (Figure 10A) and reduced the
glimepiride-induced suppression of TNF secretion in
response to PrP82-146, Aβ42 and αSN (Figure 10B) or
LPS (Figure 10C). Primary microglial cells behaved in a
similar manner to the RAW 264 cells in that the
glimepiride-induced suppression of PrP82-146 and
Aβ42-TNF production was reversed by the inclusion of
200 μM p-CMPS (Figure 10D).Figure 9 RAW 264 cells digested with PI-PLC are hyporesponsive
to lipopolysaccharide (LPS). (A) The concentrations of TNF produced
by RAW 264 cells pre-treated with control medium (●), PI-PLC (○) or
heat-inactivated PI-PLC (■) and incubated with LPS. Values are
means ± SD from triplicate experiments performed 4 times, n = 12. (B)
The concentrations of IL-1β produced by RAW 264 cells pre-treated
with control medium (●), PI-PLC (○) or heat-inactivated PI-PLC (■) and
incubated with LPS. Values are means ± SD from triplicate experiments
performed 4 times, n = 12. (C) The concentrations of IL-6 produced by
RAW 264 cells pre-treated with control medium (●), PI-PLC (○) or heat-
inactivated PI-PLC (■) and incubated with LPS. Values are means ± SD
from triplicate experiments performed 4 times, n = 12.
Figure 10 Glimepiride induced immunosuppression is reversed
by pCMPS. (A) The amounts of CD14 in RAW 264 cells treated for 1
hour with control medium or 5 μM glimepiride in the presence of
control medium (□) or 200 μM pCMPS (■). Values are means ± SD
from triplicate experiments performed 4 times, n = 12. *CD14
significantly greater than those of cells treated with glimepiride.
(B) The concentrations of TNF produced by RAW 264 cells pre-treated
with control medium (□), 5 μM glimepiride (■), or 5 μM glimepiride
and 200 μM pCMPS (striped bars) and incubated with 50 μM PrP82-
146, 50 μM Aβ1–42 or 50 μM αSN. Values are means ± SD from triplicate
experiments performed 4 times, n = 12. *TNF significantly less than
control cells incubated with peptides. (C) The concentrations of TNF
produced by RAW 264 cells pre-treated with control medium (●), 5 μM
glimepiride (○) or 5 μM glimepiride and 200 μM pCMPS (■) and
incubated with LPS as shown. Values are means ± SD from triplicate
experiments performed 4 times, n = 12. (D) The concentrations of TNF
produced by microglial cells pre-treated with control medium (□), 5
μM glimepiride (■), or 5 μM glimepiride and 200 μM pCMPS (striped
bars) and incubated with 50 μM PrP82-146 or 50 μM Aβ1–42. Values are
means ± SD from triplicate experiments performed twice, n = 6. *TNF
significantly less than control cells incubated with peptides.
Figure 11 CD14 mediates cytokine secretion from peptide
stimulated RAW 264 cells. (A) The concentrations of TNF
produced by RAW 264 cells pre-treated with antiserum to CD14 (■),
PrPC (□) or CD55 (striped bars) and incubated with 50 μM PrP82-146,
Aβ1–42 or αSN. Values are means ± SD from triplicate experiments
performed 3 times, n = 9. *TNF significantly less than those of
control cells incubated with peptides. (B) The concentrations of TNF
produced by microglial cells derived from CD14 wild type (□) or
CD14 knockout (■) mice incubated with PrP82-146 or Aβ1–42. Values
are means ± SD from triplicate experiments performed 3 times,
n = 9. *TNF significantly less than those from CD14 wild type cells
incubated with peptides.
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These results are consistent with the hypothesis that the
inhibitory effects of glimepiride on cytokine secretion
were mediated through a GPI-anchored protein, and
while CD14 is known to be involved in LPS-induced
cytokine secretion [25], other GPI-anchored proteins
such as the cellular prion protein (PrPC) and CD55 may
also be involved in the activation of macrophages
[26,38]. To determine which of these receptors were
critical for peptide-induced cytokine production RAW
264 cells were pre-treated with antibodies to CD14, PrPC
or CD55. Pre-treatment of RAW 264 cells with anti-
serum to CD14 but not by antiserum to PrPC or to
CD55 reduced TNF secretion from RAW 264 cellsincubated with PrP82-146, Aβ42 or αSN (Figure 11A) in-
dicating that CD14 is a major receptor involved in
peptide-induced TNF secretion. This hypothesis was
strengthened by observations that microglial cells de-
rived from CD14 knockout mice produced less TNF
than microglial cells derived from CD14 wild type mice
Figure 12 PrP82-146 causes the translocation of Toll-like receptor
(TLR)-4 into rafts. (A) The % of TLR-4 in DRMs derived from RAW 264
cells treated with PrP82-146 (●) or PrP82-146scrambled (○). Values are
means ± SD from triplicate experiments performed 3 times, n = 9.
(B) The % TLR-4 in DRMs derived from RAW 264 cells treated with
control medium (□) or 50 μM Aβ1–42, Aβ42–1, αSN or βSN as shown (■).
Values are means ± SD from triplicate experiments performed 3 times,
n = 9. *TLR-4 significantly greater than those of control cells. (C) RAW
264 cells were incubated with PrP82-146 (○), Aβ1–42 (●) or αSN (□) (6
to 50 μM). There were significant correlations between % TLR-4 in rafts
and TNF for PrP82-146, Pearson’s coefficient = 0.88, Aβ1–42, Pearson’s
coefficient = 0.78 and αSN Pearson’s coefficient = 0.86. (D) There was a
significant correlation between the % TLR-4 in rafts of RAW 264 cells
incubated with lipopolysaccharide (LPS) (0.75 to 50 ng/ml) and TNF
produced, Pearson’s coefficient = 0.887.
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Notably, TNF secretion from microglial cells derived
from PrPC knockout mice was not significantly different
from microglia derived from Prnp wild type mice when
incubated with PrP82-146 or Aβ42 (data not shown).
Our results suggest that the immunosuppressant ef-
fects of glimepiride were mediated by the reduced ex-
pression of CD14, a molecule that acts as a receptor for
LPS and neurotoxic peptides associated with prion,
Alzheimer’s disease and Parkinson’s disease. To deter-
mine if glimepiride reduced the uptake of neurotoxic
peptides to RAW 264 cells, glimepiride-treated cells
were incubated with 50 μM PrP82-146 or 50 μM Aβ42
for 2 hours. Pre-treatment with 5 μM glimepiride did
not significantly alter the concentration of PrP82-146
(43 μM± 5 compared with 41 μM± 7, n = 9, P = 0.5) or
Aβ42 (39 μM± 8 compared with 40 μM± 7, n = 9, P = 0.7)
in RAW 264 cells.
Peptides cause the translocation of TLR-4 into membrane rafts
Since signalling complexes formed around CD14 also
include TLR-4 [26], the effects of macrophage stimulants
upon TLR-4 was studied. Firstly we showed that the
amounts of TLR-4 in RAW-264 cells were not signifi-
cantly altered by the addition of either 50 μM PrP82-146
(100 units ± 5 compared with 98 units ± 7, n = 9, P = 0.62)
or 50 μM Aβ42 (100 units ± 5 compared with 97 units ± 8,
n = 9, P = 0.49). The formation of signalling complexes in-
volves the recruitment of TLR-4 into specific detergent-
resistant membranes commonly called lipid rafts [39,40].
Here we show that the addition of PrP82-146, but not
the control peptide (PrP82-146scrambled), caused a dose-
dependent increase in the amounts of TLR-4 within
(DRMs) rafts (Figure 12A). The amounts of TLR-4 in rafts
was also increased after the addition of 50 μM Aβ1–42
or αSN, but were not affected by 50 μM Aβ42–1 or βSN
(Figure 12B). After RAW 264 cells were incubated with
different concentrations of PrP82-146, Aβ1–42 or αSN
there was a significant correlation between the amounts of
TLR-4 within rafts and the amounts of TNF produced
(Figure 12C). Similar results were obtained when RAW-
264 cells were incubated with LPS; namely that LPS-
caused TLR-4 to migrate into rafts and that there was a
significant correlation between the amounts of TLR-4 in
rafts and TNF production (Figure 12D).
Glimepiride reduces the peptide-induced translocation of
TLR-4 into membrane rafts
Treatment of RAW264 cells with 5 μM glimepiride did
not affect the amounts of TLR-4 either in whole cells
(100 units ± 5 compared with 99 units ± 7, n = 9, P =
0.71) or within DRMs (rafts) (21 units ± 3 compared
with 20 units ± 6, n = 9, P = 0.58). Next, we showed that
pre-treatment with 5 μM glimepiride reduced theamounts of TLR-4 in rafts in cells incubated with 50 μM
PrP82-146 (Figure 13A), 50 μM Aβ1–42 (Figure 13B), 50
μM αSN (Figure 13C) or 10 ng/ml LPS (Figure 13D).
Pre-treatment of RAW 264 cells with 5 μM glipizide did
not affect either peptide or LPS-induced translocation of
TLR-4 into DRMs.Discussion
There is accumulating evidence that inflammation exac-
erbates the symptoms and accelerates the progression of
AD and PD [10-12]. Consequently, glial cells activated
by aggregated proteins are seen as a therapeutic target.
Here we show that physiologically relevant concentra-
tions of glimepiride [41] result in the release of several
GPI-anchored proteins from RAW 264 and microglial
cells consistent with reports that this drug activates an
endogenous GPI-PLC [33,34]. Glimepiride treatment of
RAW 264 cells also resulted in lower concentrations of
cytokine secretion when these cells were incubated with
PrP82-146, Aβ42 or αSN.
The role of cytokines in neurodegenerative diseases is
controversial, although TNF has been reported to protect
Figure 13 Glimepiride reduces the translocation of Toll-like
receptor (TLR)-4 to rafts. (A) The % TLR-4 in rafts of RAW 264 cells
pre-treated with control medium, 5 μM glimepiride or 5 μM glipizide
and incubated with control medium (□) or 50 μM PrP82-146 (■).
Values are means ± SD from triplicate experiments performed 4
times, n = 12. *TLR-4 significantly less than those of control cells
incubated with PrP82-146. (B) The % TLR-4 in rafts of RAW 264 cells
pre-treated with control medium, 5 μM glimepiride or 5 μM glipizide
and incubated with control medium (□) or 50 μM Aβ1–42 (■). Values
are means ± SD from triplicate experiments performed 4 times,
n = 12. *TLR-4 significantly less than those of control cells incubated
with Aβ1–42. (C) The % TLR-4 in rafts of RAW 264 cells pre-treated
with control medium, 5 μM glimepiride or 5 μM glipizide and
incubated with control medium (□) or 50 μM αSN (■). Values are
means ± SD from triplicate experiments performed 4 times, n = 12.
*TLR-4 significantly less than those of control cells incubated with
αSN. (D) The % TLR-4 in rafts of RAW 264 cells pre-treated with
control medium, 5 μM glimepiride or 5 μM glipizide as shown and
incubated with control medium (□) or 10 ng/ml LPS (■). Values are
means ± SD from triplicate experiments performed 4 times, n = 12.
*TLR-4 significantly less than those of control cells incubated with
lipopolysaccharide (LPS).
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that elevated concentrations of cytokines increase neuro-
degeneration. Thus, elevated levels of TNF are reported
in neurodegenerative conditions including AD and PD
[44,45], inhibition of TNF prevents neuropathology in
mouse models of AD and post-operative cognitive decline
[46,47] and the TNF inhibitor etanercept causes cognitive
improvement in AD patients [48]. Similarly, high levels
of IL-6 are raised in the brain tissue or cerebrospinal
fluid (CSF) in AD, AIDS dementia complex, multiple
sclerosis, stroke, PD and traumatic brain injuries [49] and
IL-6 receptors are expressed on neurons at synapses and
can regulate neurotransmitter release [50,51]. As a conse-
quence of these observations it is thought that compounds
that reduce cytokine production are likely to reduce
neurodegeneration.As glimepiride would be expected to decrease the ex-
pression of many GPI-anchored proteins, including
CD14, PrPC and CD55 - proteins which are implicated/
involved in cytokine production [25,26,52] - it was not
clear which GPI-anchored protein was responsible for
cellular responses to aggregated peptides. However we
found that CD55 expression was not affected by glime-
piride and that antiserum to CD55 did not affect
peptide-induced cytokine production. Although glime-
piride reduced the PrPC content of RAW 264 cells, cyto-
kine production was not affected by antiserum to PrPC.
In contrast, antiserum to CD14 blocked peptide- and
LPS-induced cytokine production. In addition, microglia
from CD14 knockout mice produced fewer cytokines
than microglia from CD14 wild type mice when incu-
bated with PrP82-146 or Aβ1–42. Collectively, these re-
sults indicate that it is the loss of CD14 that is the key
element in glimepiride-induced suppression of cytokine
production. The loss of CD14 from glimepiride-treated
cells was accompanied by a corresponding increase of
CD14 in cell supernatants, showing that CD14 was re-
leased from cells rather than degraded.
The expression of CD14 is increased in animal models
of AD and PD [53] and CD14 is involved in microglial
recognition to Aβ fibrils [16] and prion-damaged neurons
[24]. Although pre-treatment with glimepiride signifi-
cantly reduced the amounts of TNF and IL-6 produced by
RAW 264 and microglial cells incubated with PrP82-146,
αSN or Aβ42, it did not reduce the binding of PrP82-146
or Aβ42 to RAW 264 cells. Thus, although the presence of
soluble CD14 in cell supernatants may bind to PrP or Aβ
peptides, such complexes still interacted with cells. Fur-
thermore, cells treated with glimepiride and then washed,
so as to remove any soluble CD14, remained hyporespon-
sive to PrP and Aβ peptides indicating that soluble CD14
alone was not sufficient to explain the immunosuppressive
effects of glimepiride. These observations indicate that al-
though cells bind these peptides in a CD14-independent
manner, cytokine production is dependent upon the
engagement of CD14. Recently, the deletion of CD14 was
shown to attenuate AD-like pathology in a transgenic
murine model of AD [27] suggesting that CD14-dependent
microglial responses to aggregated Aβ are a major driver of
the pathology in AD.
Insulin-induced activation of a GPI-PLC generates sec-
ond messengers that mediate the intracellular effects of
insulin [54]. Since glimepiride mimics the effects of insu-
lin upon GPI-PLC [33,55], we hypothesise that it is the
glimepiride-induced activation of an endogenous GPI-
PLC that leads to the release of CD14 and the suppres-
sion of cytokine production. This idea was supported by
two observations; firstly, that RAW 264 cells digested
with PI-PLC were similar to glimepiride-treated cells in
that they contained less CD14 and secreted less
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p-CMPS, a selective inhibitor of GPI-PLC [37], reversed
the effects of glimepiride on cellular levels of CD14 and
cytokine production.
These observations may have implications beyond
neurodegenerative diseases as the pathogenesis associ-
ated with many acute infectious diseases may be partly
caused following excessive cytokine release by macro-
phages. For example, LPS is considered to be the major
macrophage stimulant leading to excessive cytokine pro-
duction in gram negative bacterial infections. CD14 was
identified as a receptor that mediates LPS-induced cell
activation [25] and in some animal models, CD14
knockout mice are resistant to acute septicaemia [56]
suggesting that the induction of cytokines via a CD14-
dependent mechanism is critical for pathogenesis. Here
we show that glimepiride treatment also reduced the
LPS-induced secretion of TNF and IL-6. While these re-
sults suggest that the loss of CD14 was responsible for
the hyporesponsive state of glimepiride-treated macro-
phages, we noted that glimepiride would be expected to
decrease surface expression of other GPI-anchored pro-
teins, and some of these might be responsible for LPS-
induced responses. PrPC and CD55 are GPI-anchored
proteins which have been implicated in LPS signalling
[26]. The predominant role of CD14 in LPS-induced
cytokine production in these experiments was demon-
strated by both CD14 knockout microglia and neutralis-
ing antiserum to CD14.
As glimepiride did not reduce the binding of LPS or
neurotoxic peptides to macrophages we investigated cell
signalling in these cells. The binding of LPS to CD14
does not initiate cell activation alone; rather it is the first
step in the formation of a signalling complex. Thus,
CD14 acts as a co-receptor for TLR-4 which mediates
activation of myeloid cells [26]. CD14 is targeted to
membrane rafts which, in quiescent cells, exist as micro-
domains ranging from 5 to 200 nm in diameter [57,58]
and which are ‘poised’ to form larger rafts [59] and co-
alesce under specific stimuli to form a larger signalling
platform [57,59-62]. The coalescence of individual rafts
may bring together receptors and signalling proteins
into a functional complex; for example the LPS-induced
formation of CD14:MD2:TLR-4 complexes [63]. Not-
ably, this tri-receptor complex is necessary for activa-
tion of microglia by Aβ [64] and TLR-4 is associated
with increased cytokine production in murine AD
models [65,66].
The reorganisation of rafts in the outer membrane
leaflet in response to external stimuli can result in the
sorting of intracellular signalling molecules on the cyto-
plasmic leaflet [67-70] and consequently cell activation.
For example, extracellular LPS has been shown to re-
cruit the key signalling protein TLR-4 to rafts followingengagement of specific receptors [26,63,70] and activate
intracellular signalling pathways leading to cytokine pro-
duction. In this study we demonstrate that PrP82-146,
Aβ1–42 or αSN also caused the translocation of TLR-4
into rafts and that there was a significant correlation be-
tween the amounts of TLR-4 within rafts and cell activa-
tion as measured by cytokine production. Critically, this
translocation of TLR-4 into rafts was reduced in cells
treated with glimepiride.
Conclusions
Novel approaches of treating neurodegenerative condi-
tions are urgently required. Here we show that glimepir-
ide triggered the release of CD14 from RAW 264 cells
consistent with activation of an endogenous GPI-PLC
and the shedding of GPI-anchored proteins including
CD14 from RAW 264 cells. Consequently, glimepiride
treatment significantly reduced cytokine secretion from
RAW 264 cells incubated with PrP82-146, Aβ1–42 or
αSN. Such observations suggest that glimepiride may re-
duce cytokine secretion and hence neuroinflammation
in neurodegenerative diseases and should be considered
as a novel adjunctive treatment for AD.
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